Manel Ciria Recasens *

Autor invitado por SIIC

En este estudio se objetiva un mayor efecto anabólico del complejo de oseína-hidroxiapatita, a la dosis de 1.660 mg/12 h, que del carbonato cálcico, a la dosis de 1.250 mg/12 h, evaluado mediante los niveles de osteocalcina sérica.

EFICACIA OSTEOGÉNICA DEL COMPLEJO DE OSEÍNA-HIDROXIAPATITA EN MUJERES CON OSTEOPOROSIS

El tratamiento de la osteoporosis sin fractura en nuestra muestra de mujeres mayores de 65 años con el complejo de oseína-hidroxiapatita y vitamina D se asocia a una formación ósea significativamente superior a la observada con el tratamiento con carbonato cálcico y vitamina D. Este mayor estímulo formador óseo junto a una mayor tendencia a la preservación de la densidad mineral ósea podría asociarse a un menor riesgo de fractura.

*Manel Ciria Recasens
describe para SIIC los aspectos relevantes de su trabajo
COMPARISON OF THE EFFECTS OF OSSEIN-HYDROXYAPATITE COMPLEX AND CALCIUM CARBONATE ON BONE METABOLISM IN WOMEN WITH SENILE OSTEOPOROSIS: A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, CONTROLLED, PROSPECTIVE STUDY
Institución principal de la investigación
*Parc de Salut Mar, Servicio de Reumatología., Barcelona, España
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
1. Melton LJ. How many women have osteoporosis now? J Bone Miner Res 10:175-7, 1995.
2. Diez A, Puig J, Martinez MT, et al. Epidemiology of fractures of the proximal femur associated with osteoporosis in Barcelona, Spain. Calcif Tissue Int 44:382-6, 1989.
3. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-8, 2002.
4. Zethraeus N, Borgstrom F, Strom O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis. A review of the literature and a reference model. Osteoporos Int 18:9-23, 2007.
5. Riggs BL, Melton LJ. Involutional osteoporosis. N Engl J Med 314:1676-86, 1986.
6. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259, 1996.
7. Schott AM, Cormier C, Hans D, et al. How hip and whole body bone mineral density predict hip fracture in elderly women. The EPIDOS prospective study. Osteoporos Int 8:247-254, 1998.
8. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 15:183-187, 2000.
9. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592, 2002.
10. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599-604, 2004.
11. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18:141-150, 1996.
12. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340, 2001.
13. Prince RL, Devine A, Dhaliwal SS, et al. Effects of calcium supplementation on clinical fracture and bone structure. Arch Intern Med 166;869-75, 2006.
14. Cumming R, Cumming S, Nevitt M. Calcium intake and fracture risk: results from the study of osteoporotic fractures. Am J Epidemiol 145:927-935, 1997.
15. Shea B, Wells G, Cranney A, et al. (2002) VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 23:552-559, 2002.
16. Shea B, Wells G, Cranney A, et al. Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev 1:CD004526, 2001.
17. Felsenberg D, Boonen S. The Bone Quality Framework: determinants of bone strength and their interrelationship, and implications for osteoporosis management. Clin Ther 27:1-11, 2005.
18. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010. Accessible at http://www.nof.org/professionals/clinical-guidelines.
19. Annefeld M, Caviezel R, Schacht E, et al. The influence of osseín-hydroxyapatite compound on the healing of a bone defect. Curr Med Res Opin 10:241-250, 1986.
20. Schmidt KH, Wörner VM, Buck HJ. Examination of new bone growth on aluminium oxide implant contact surfaces after oral administration of ossein-hydroxyapatite compound to rats. Curr Med Res Opin 11:107-15, 1988.
21. Chavassieux P, Pastoreau P, Boivin G, et al. Effects of ossein-hydroxyapatite compound on ewe bone remodelling: biochemical and histomorphometric study. Clin Rheumatol 10:269-73, 1991.
22. Castelo Branco C, Vicente JJ, Haya J. Complejo de oseína-hidroxiapatita. En: Castelo Branco C, Haya Palazuelos J, eds. Osteoporosis y menopausia. Pp 357-364.
23. Ruegsegger P, Keller A, Dambacher MA. Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. Osteoporos Int 5:30-4, 1995.
24. Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-48, 1993.
25. Castelo Branco C, Pons F, Vicente JJ, et al. Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial. J Reprod Med 44:601-5, 1999.
26. Pelayo I, Haya J, De la Cruz JJ et al. Raloxifene plus ossein-hydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial. Menopause 15:1132-8, 2008.
27. Castelo Branco C, Ciria Recasens M, Cancelo Hidalgo MJ, et al. Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss: a meta-analysis. Menopause 16:984-91, 2009.
28. Delmas PD, Eastell R, Garnero P et al. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11:2-17, 2000.
29. Cranney A, Horsley T, O'Donnell S et al. Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess 158:1-235, 2007.

Otros artículos de Manel Ciria Recasens

Cancelo Hidalgo MJ, Castelo Branco C, Palacios S, Haya Palazuelos J, Ciria Recasens M, Manasanch J, Pérez Edo L. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin 29(4):291-303, 2013.
Pérez Edo L, Alonso Ruiz A, Roig Vilaseca D, García Vadillo A, Guañabens Gay N, Peris P, Torrijos Eslava A, Beltrán Audera C, Fiter Aresté J, Arboleya Rodríguez L, Graña Gil J, Carbonell Abelló J, Nolla JM, Holgado Pérez S, Salas Heredia E, Zubieta Tabernero J, Del Pino Montes J, Blanch i Rubió J, Caamaño Freire M, Rodríguez Pérez M, Castañeda S, Cerdá D, Gómez Vaquero C, Calvo Catalá J, Ciria M, Loza E; Spanish Society of Rheumatology. 2011 Up-date of the consensus statement of the Spanish Society of Rheumatology on osteoporosis. Reumatol Clin 7(6):357-79, 2011.
Arboleya L, Díaz Curiel M, Del Río L, Blanch J, Díez Pérez A, Guañabens N, Quesada JM, Sosa M, Gómez C, Muñoz Torres M, Ramírez E, Combalia J; OSTEOXPRESS study investigators. Prevalence of vertebral fracture in postmenopausal women with lumbar osteopenia using MorphoXpress® (OSTEOXPRESS Study). Aging Clin Exp Res 22(5-6):419-26, 2010.
Ruiz Gaspà S, Blanch Rubió J, Ciria Recasens M, Monfort J, Tío L, García Giralt N, Nogués X, Monllau JC, Carbonell Abelló J, Pérez Edo L. Reduced proliferation and osteocalcin expression in osteoblasts of male idiopathic osteoporosis. Calcif Tissue Int 86(3):220-6, 2010.
Castelo Branco C, Ciria Recasens M, Cancelo Hidalgo MJ, Palacios S, Haya Palazuelos J, Carbonell Abelló J, Blanch Rubió J, Martínez Zapata MJ, Manasanch J, Pérez Edo L. Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss: a meta-analysis. Menopause 16(5):984-91, 2009.
Docampo E, Ciria M, Serra Burgés J, Blanch J, Pérez Edo L, Carbonell J. Risk factors of new fractures after vertebroplasty. Med Clin (Barc) 133(1):17-9, 2009.
Agueda L, Bustamante M, Jurado S, Garcia Giralt N, Ciria M, Saló G, Carreras R, Nogués X, Mellibovsky L, Díez Pérez A, Grinberg D, Balcells S. A haplotype-based analysis of the LRP5 gene in relation to osteoporosis phenotypes in Spanish postmenopausal women. J Bone Miner Res 23(12):1954-63, 2008.
Bustamante M, Nogués X, Agueda L, Jurado S, Wesselius A, Cáceres E, Carreras R, Ciria M, Mellibovsky L, Balcells S, Díez Pérez A, Grinberg D. Promoter 2 -1025 T/C polymorphism in the RUNX2 gene is associated with femoral neck bmd in Spanish postmenopausal women. Calcif Tissue Int 81(4):327-32, 2007.
Ciria Recasens M, Pérez Edo L, Blanch Rubió J, Mariñoso ML, Benito Ruiz P, Serrano S, Carbonell Abelló J. Bone histomorphometry in 22 male patients with normocalciuric idiopathic osteoporosis. Bone 36(5):926-30, 2005.
Pérez Edo L, Ciria Recasens M, Castelo Branco C, Orozco López P, Gimeno Marqués A, Pérez C, Manasanch Dalmau J. Management of osteoporosis in general practice: a cross-sectional survey of primary care practitioners in Spain. Osteoporos Int 15(3):252-7, 2004.

Para comunicarse con Manel Ciria Recasens mencionar a SIIC como referencia:
jose.manasanch@pierre-fabre.es

---

Acerca del trabajo completo

EFICACIA OSTEOGÉNICA DEL COMPLEJO DE OSEÍNA-HIDROXIAPATITA EN MUJERES CON OSTEOPOROSIS

Título original en castellano
COMPARACION DE LOS EFECTOS DEL COMPLEJO DE OSEINA-HIDROXIAPATITA Y DEL CARBONATO CALCICO EN EL METABOLISMO OSEO EN MUJERES CON OSTEOPOROSIS SENIL: ESTUDIO CONTROLADO, ALEATORIZADO, PROSPECTIVO, ABIERTO Y DE GRUPOS PARALELOS.

Autores
Manel Ciria Recasens¹, Josep Blanch Rubió², Mónica Coll Batet³, María Del Pilar Lisbona Pérez⁴, Adolfo Díez Perez⁵, Jordi Carbonell Abelló⁶, José Manasanch⁷, Lluís Pérez Edo⁸
1 Médico, Parc de Salut Mar, Servicio de Reumatología., Barcelona, España, Médico Adjunto
2 Médico, Parc de Salut Mar
3 Médico
4 Médico
5 Médico, Parc de Salut Mar
6 Médico, Parc de Salut Mar
7 Médico, Pierre Fabre Ibérica S.a.
8 Médico

Acceso a la fuente original
Clinical Drug Investigation
http://www.springer.com/adis/journal/40261

El artículo se relaciona estrictamente con las especialidades de siicsalud
El artículo se conecta secundariamente con las especialidades